666 related articles for article (PubMed ID: 8722359)
1. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
2. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
Hebart H; Müller C; Löffler J; Jahn G; Einsele H
Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
[TBL] [Abstract][Full Text] [Related]
5. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
9. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
10. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
Ljungman P; Oberg G; Aschan J; Ehrnst A; Lönnqvist B; Pauksen K; Sulila P
Bone Marrow Transplant; 1996 Sep; 18(3):565-8. PubMed ID: 8879618
[TBL] [Abstract][Full Text] [Related]
11. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
[TBL] [Abstract][Full Text] [Related]
12. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.
Matsunaga T; Sakamaki S; Ishigaki S; Kohda K; Takeda M; Katoh J; Kuroda H; Hirayama Y; Kusakabe T; Akiyama T; Kuga T; Niitsu Y; Masaoka T; Sagawa T; Matsumoto Y
Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460
[TBL] [Abstract][Full Text] [Related]
13. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
[TBL] [Abstract][Full Text] [Related]
14. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
16. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
20. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
